MAP2K7 and ovarian carcinoma: These observations are consistent with reports elsewhere of early decreases in [18 F]FDG uptake for mTOR inhibition in experimental lymphoma model [33], and for combined PI3K/mTOR (PF-04691502) and MEK (PD-0325901) inhibitors in a K-rasG12D; Pten mutated mouse model of ovarian cancer [34].